ArticleMolecular pharmacology2009
D5 dopamine receptors are required for dopaminergic activation of phospholipase C.
Article in Molecular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- The Signaling and Pharmacology of the Dopamine D1 Receptor.Frontiers in cellular neuroscience · 2021Pooled it
- Analysis of clinical trials on drugs targeting dopamine receptors: a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Differences in the Effect of Dopamine on the Phototransduction Between Lampreys and Jawed Vertebrates.International journal of molecular sciences · 2026Article
- Interaction Between Oxytocin and Dopamine Signaling: Focus on the Striatum.International journal of molecular sciences · 2025Review
- Dopamine D1-Like Receptor Stimulation Induces CREB, Arc, and BDNF Dynamic Changes in Differentiated SH-SY5Y Cells.Neurochemical research · 2024Article
- Dopamine internalization via UptakeFrontiers in pharmacology · 2024Article
- Modulation of Neuron and Astrocyte Dopamine Receptors via Receptor-Receptor Interactions.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Dopaminergic Modulation of Prefrontal Cortex Inhibition.Biomedicines · 2023Review
- Dopamine, Immunity, and Disease.Pharmacological reviews · 2023Review
- Behavioral characteristics of dopamine DScientific reports · 2022Article
- Ankyrin Repeat and Kinase Domain Containing 1 Gene, and Addiction Vulnerability.International journal of molecular sciences · 2020Review
- The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.Scientific reports · 2020Article
- Dopamine increases HIV entry into macrophages by increasing calcium release via an alternative signaling pathway.Brain, behavior, and immunity · 2019Article
- Role of Descending Dopaminergic Pathways in Pain Modulation.Current neuropharmacology · 2019Review
- Dopamine: Functions, Signaling, and Association with Neurological Diseases.Cellular and molecular neurobiology · 2019Review
- Activation of D1/5 Dopamine Receptors in the Dorsal Medial Prefrontal Cortex Promotes Incubated-Like Aversive Responses.Frontiers in behavioral neuroscience · 2017Article
- G protein-coupled receptor kinases as regulators of dopamine receptor functions.Pharmacological research · 2016Review
- Postnatal development of the dopaminergic signaling involved in the modulation of intestinal motility in mice.Pediatric research · 2016Article
- The Addiction-Related Gene Ankk1 is Oppositely Regulated by D1R- and D2R-Like Dopamine Receptors.Neurotoxicity research · 2016Article
- Dopamine-sensitive signaling mediators modulate psychostimulant-induced ultrasonic vocalization behavior in rats.Behavioural brain research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Dopamine activates phospholipase C in discrete regions of the mammalian brain, and this action is believed to be mediated through a D(1)-like receptor. Although multiple lines of evidence exclude a role for the D(1) subtype of D(1)-like receptors in the phosphoinositide response, the D(5) subtype has not been similarly examined. Here, mice lacking D(5) dopamine receptors were tested for dopamine agonist-induced phosphoinositide signaling both in vitro and in vivo. The results show that hippocampal, cortical, and striatal tissues of D(5) receptor knockout mice significantly or completely lost the ability to produce inositol phosphate or diacylglycerol messengers after stimulation with dopamine or several selective D(1)-like receptor agonists. Moreover, endogenous inositol-1,4,5-trisphosphate stimulation by the phospholipase C-selective D(1)-like agonist 3-methyl-6-chloro-7,8-dihydroxy-1-[3methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine (SKF83959) was robust in wild-type animals but undetectable in the D(5) receptor mutants. Hence, D(5) receptors are required for dopamine and selective D(1)-like agonists to induce phospholipase C-mediated phosphoinositide signaling in the mammalian brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.